Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $145 to $130.
Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $130
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.